With 5% CAGR Paracetamol Market is expected to grow US$15.03 billion by 2031, surging amid the Growing Pharmaceutical Industry | The Insight Partners

NEW YORK, Sept. 23, 2025 /PRNewswire/ -- A new in-depth report by The Insight Partners highlights paracetamol market growth, driven by a rise in chronic pain and fever-related disorders. The comprehensive analysis dives into market size, emerging trends, profiles key industry players, and uncovers strategic opportunities shaping the industry landscape. With a spotlight on key market segments and applications, the paracetamol report highlights the factors that drive market momentum in the years ahead.

Increasing Usage of Paracetamol as an Over-The-Counter (OTC) Analgesic and Antipyretic Set to Shape Industry Outlook

Check valuable insights in the Paracetamol Market report. You can easily get a sample PDF of the report - https://www.theinsightpartners.com/sample/TIPRE00038952

Paracetamol Market Set to Soar with Demand for Over-The-Counter (OTC) Analgesics
Valued at US$10.75 billion in 2024. The market is projected to reach US$15.03 billion by 2031, registering a strong CAGR of 5.0% (2025–2031). This growth is driven by a rise in the prevalence of chronic pain and fever-related disorders and the wide usage of paracetamol as an over-the-counter (OTC) analgesic and antipyretic.

Paracetamol, or acetaminophen, is a non-opioid analgesic and antipyretic agent used to treat fever and mild to moderate pain. It is mainly available over the counter and sold under several brand names, including Tylenol and Panadol.

Future market opportunities lie in the growing demand for intravenous (IV) paracetamol in clinical settings, expanding e‑commerce and online pharmacies, and emerging markets and regional expansion.

Rise in Prevalence of Chronic Pain and Fever-Related Disorders

Chronic pain is increasingly recognized as a profound and expanding public health challenge worldwide. It now affects roughly one in five adults globally—equivalent to more than 1.5 billion people. In India, for example, a community study estimated that about 19.3% of adults suffer chronic pain, roughly 180–200 million individuals, with previous surveys suggesting even higher rates in some regions, as per PubMed Central. These intersecting trends—a rising population with chronic pain and fever episodes, persistent under-treatment, health inequities, and structural factors accelerating both types of disorders—are driving sustained and increasing consumption of over-the-counter antipyretic/analgesics such as paracetamol.